Brind.
  1. MannKind Corporation announced that a target action date was set for the pediatric use of inhaled insulin, involving the FDA.

MannKind Corporation met with the FDA regarding its plan file for approval.

6 reports, 4 independent Updated Oct 1
Gone quiet
Reports
6
Developments
4
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

MannKind Corporation met with the FDA regarding its plan file for approval.

Who's involved

What this event is mainly about
FDAMannKind Corporation

How it developed

Newest first. Tap a step to see who reported it.
  1. ReadyFlow shows comparable performance to On-body Infusor and is supported by Ajay Ahuja.1 source
  2. Update on drug trial decisions and royalty streams involving FDA review.1 source
  3. MannKind met FDA plan file for approval for its inhaled insulin product.1 source
  4. Dr. Haller appointed to chair the Phase 3 study for MannKind Corporation.

Keep exploring

Part of

MannKind Corporation announced that a target action date was set for the pediatric use of inhaled insulin, involving the FDA. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story